OAK HILL BIO
Current Employees Featured
More informations about "oak hill bio"
News — Oak Hill Bio
Nov 4, 2024 Chiesi Group and Oak Hill Bio announce License and Development Agreement to develop, manufacture, and commercialize OHB-607, a potentially transformative neonatal …See details»
oak hill bio - Crunchbase Company Profile & Funding
Oak hill bio is a clinical-stage rare disease therapeutics company developing life-changing medicines. New. Resources. Advanced Search. ... Experience the new Crunchbase, powered …See details»
Our Programs - Oak Hill Bio
Oak Hill Bio’s preclinical programs bring exciting potential. OHB-201, OHB-211 and OHB-301 are companion programs to OHB-101. They provide nuanced mechanisms compared to OHB-101 …See details»
Oak Hill Bio Announces Formation of Board of Directors
Apr 12, 2022 Oak Hill Bio was established with the acquisition and license of two clinical-stage and four preclinical investigational therapeutics from Takeda Pharmaceutical Company Limited (“Takeda”).See details»
Oak Hill Bio - PitchBook
Oak Hill Bio was founded in 2022. Where is Oak Hill Bio headquartered? Oak Hill Bio is headquartered in Altrincham, United Kingdom. What is the size of Oak Hill Bio? Oak Hill Bio has 10 total employees. What industry is Oak Hill Bio in? …See details»
oak hill bio - Drug pipelines, Patents, Clinical trials - Synapse
Last update 21 Mar 2024. oak hill bio. Private Company |See details»
Oak Hill Bio Joins C-Path's International Neonatal Consortium
TUCSON, Ariz., Aug. 24, 2022 — Critical Path Institute (C-Path) today announced that Oak Hill Bio (Oak Hill), a clinical-stage neonatology and rare disease therapeutics company, has …See details»
oak hill bio - Updates, News, Events, Signals & Triggers - Crunchbase
This collaboration, highlighted in multiple news sources, suggests an expansion of oak hill bio's operations and a potential increase in revenue streams. Furthermore, the attention from a …See details»
oak hill bio - Contacts, Employees, Board Members ... - Crunchbase
Organization. oak hill bio . Connect to CRM . Save . Summary. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 2. Contacts 11. ... oak hill bio has 2 …See details»
Oak Hill Bio Announces Promotion of Josh Distler to Chief …
CAMBRIDGE, Mass., October 7, 2024 — Oak Hill Bio, a clinical-stage neonatology and rare disease therapeutics company, today announced the promotion of Josh Distler, J.D. to Chief …See details»
Oak Hill Bio Overview | SignalHire Company Profile
Oak Hill Bio Overview Contact top employees from Oak Hill Bio Summary. oak hill bio is a clinical-stage rare disease therapeutics company developing life-changing medicines. ... Organization …See details»
Oak Hill Bio Announces Formation of Board of Directors
Apr 12, 2022 Oak Hill Bio, a clinical-stage neonatology and rare disease therapeutics company developing life-changing medicines for extremely preterm infants and patients suffering from …See details»
Oak Hill Bio - VentureRadar
Oak Hill Bio is committed to developing life-changing medicines for extremely preterm infants and patients suffering from rare autoimmune diseases. Our lead therapeutic candidate, OHB-607, …See details»
Oak Hill Bio and Chiesi Group Announce First Patient Enrolled in …
PARMA, Italy, May 17, 2024--Oak Hill Bio, a clinical-stage neonatology and rare disease therapeutics company, and Chiesi, an international, research-focused biopharmaceutical …See details»
Privacy Notices - Oak Hill Bio
Oak Hill Bio is a clinical stage biopharmaceutical company operating from 3rd Floor, 1 Ashley Road, Altrincham, Cheshire, UK, WA14 2DT. ... Oak Hill Bio is a multinational organization …See details»
OAK HILL BIO LTD - Companies House
People for OAK HILL BIO LTD (13746073) More for OAK HILL BIO LTD (13746073) Registered office address 3rd Floor 1 Ashley Road, Altrincham, Cheshire, United Kingdom, WA14 2DT . …See details»
Josh Distler - Co-Founder and CEO @ oak hill bio - Crunchbase
Josh Distler is the Co-Founder and CEO of oak hill bio. He previously worked at Athanor Capital as a Head of Crossover and Quantitative Equity. Josh Distler attended Harvard University. …See details»
Oak Hill Bio and Chiesi Group Announce First European Patient …
Nov 4, 2024 Oak Hill Bio and Chiesi Group are collaborating closely to develop OHB-607 under a license and development agreement. November 04, 2024 06:00 AM Eastern Standard TimeSee details»
Mecasermin rinfabate - Oak Hill Bio/ Takeda - AdisInsight - Springer
Mecasermin rinfabate (OHB 607) a recombinant version of insulin-like growth factor 1 (IGF-1), is being developed by Oak Hill Bio, under the license from Takeda, Mecasermin rinfabate - Oak …See details»